UsAgainstAlzheimer’s Statement on Discontinuation of Aduhelm

Washington, DC (January 31, 2024) — UsAgainstAlzheimer’s chair and co-founder George Vradenburg released the below statement following the announcement that Biogen will discontinue production of Aduhelm:

“We are grateful for Biogen’s leadership and continued commitment to the fight against Alzheimer’s. They are true partners in this cause.

“Fortunately, there is another drug, Leqembi, on the market patients can access and another, Donanemab, we hope will soon receive traditional approval by the FDA. We look forward to the day patients and doctors will have multiple options to choose from as they consider their treatment options.”


About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.